Hasslacher and colleagues have provided a new piece of data regarding pleiotropic eff ects of levosimendan [1] . In their elegantly designed study, the authors showed in both in vitro and in vivo experiments that levosimendan 'cools down' oxidative burst in polymorphonuclear neutrophils, and hence prevents or decreases the deleterious eff ects of reactive oxygen species.
Levosimendan is known not only to be an inodilator but also to exert cellular protective eff ects by antioxidant, anti-infl ammatory, anti-apoptotic properties [2] [3] [4] . Herein, the authors seem to puzzle out one piece of the whole pathophysiologic mechanism driving septic-shockinduced myocardial dysfunction. Interesting enough, in patients with septic shock, oxidative burst activity was cooled down in unstimulated as well as in stimulated poly morphonuclear neutrophils, whereas in patients with acute heart failure only stimulated oxidative burst was cooled down by levosimendan. We think that the clinical meaning of such a diff erential eff ect deserves to be investigated in future studies. It is possible to turn such net improvements into clinically meaningful benefi t providing that the time, route and mode of administration are well controlled.
Decreased respiratory burst activity of polymorphonuclear neutrophils in the study could possibly be driven by the membrane hyperpolarizing eff ect of levosimendan or phosphodiesterase III inhibitory eff ects, which is mainly observed at high doses. Actually, measuring plasma levels of levosimendan could have been helpful in understanding which mechanism dominated. Whatever the mechanism, such an eff ect should be kept in mind to tailor the therapy of patients suff ering from potentially hazardous complications of excess reactive oxygen species including septic shock. Of note, upon preload optimization by fl uid administration and/or vasopressor treatment in the study, levosimendan treatment seemed to be well accepted by the patients. However, the reason for the lack of a relationship between a decrease in oxidative burst and survival might be linked to the time of initiation of drug administration. Inotropic therapy is usually considered a last option in many patients, and oxidative burst could possibly have already done its irreversible injury in such patients. We think the present study provides a unique opportunity to move faster in decision-making and therapy.
